Evidence Library

Showing 10 of 96 results.
Ronald Bayer, PhD •
The Trustees of Columbia University of the City of New York
Amy Fairchild, PhD •
The Trustees of Columbia University of the City of New York

In this Perspective for the New England Journal of Medicine the authors compare US and UK approaches to harm reduction, particularly as it applies to e-cigarette policy.

 
Lainie Rutkow, JD, PhD •
Johns Hopkins University Bloomberg School of Public Health
Caleb Alexander, MD, MS •
Johns Hopkins University Bloomberg School of Public Health

The study finds Florida’s efforts to prevent inappropriate use of painkillers are showing reductions among prescribers and patients who had the highest prescribing and usage rates.

 
Corey Davis, JD, MSPH •
University of North Carolina at Chapel Hill

Drug overdose is the leading cause of injury-related death in the United States, killing more people every year than car crashes. While naloxone has been used in hospitals and ambulances for decades, the rising tide of overdose deaths has resulted in calls to make it more available to laypeople and first responders.

 
Corey Davis, JD, MSPH •
University of North Carolina at Chapel Hill

Researchers reviewed 47 prescription monitoring program (PMP) websites for overdose content. They found that most PMPs did not address overdose or related terms in available materials and few state PMPs project overdose-specific messaging or provider tools for prevention.

 
Lainie Rutkow, JD, PhD •
Johns Hopkins University Bloomberg School of Public Health

A new study released on March 2, 2015, in Health Affairs reports that most primary care physicians are aware of prescription drug monitoring programs and have used the data in their practices, but do so only intermittently.

The study surveyed 420 physicians randomly identified through the American Medical Association’s Masterfile list. Of those physicians surveyed, 72 percent were aware of their state’s prescription drug monitoring program, and 53 percent reported that they had used the programs.

 
Corey Davis, JD, MSPH •
University of North Carolina at Chapel Hill

This study, published in the American Journal of Public Health, collected and characterized all statutes and regulations effective from 1998 through 2011 governing the operation of prescription monitoring programs. As of 2011, 10 states required PMPs to report suspicious activity to law enforcement, while only three required reporting to the patient’s physician. None required linkage to drug treatment or required all prescribers to review PMP data before prescribing. Few explicitly address data retention.

 
Fernando Wilson, PhD •
University of Nebraska Medical Center

Illegal drug use is a persistent problem, prescription drug abuse is on the rise, and there is clinical evidence that drug use reduces driving performance. This study describes trends in characteristics of drivers involved in fatal motor vehicle crashes who test positive for drugs, and finds that the profile of a drugged driver has changed substantially over time. An increasing share of these drivers is now testing positive for prescription drugs, cannabis, and multiple drugs.

 
Alexander Wagenaar, PhD •
Emory University
Frank Chaloupka, PhD •
University of Illinois at Chicago, PHLR Methods Core
Beau Kilmer, PhD •
RAND
Rosalie Pacula, PhD •
RAND

This study offers lessons learned from alcohol and tobacco regulation. The researchers recommend that if states decide to experiment with marijuana policy, they should prevent retail price drops, limit marketing, and work hard to measure and prevent impaired driving. They also note the importance of adopting a state monopoly, restricting and monitoring licenses for use and distribution, restricting public consumption, and limiting the types of products sold.

 

Pages